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REFCORAbstract Background: Patterns of nodal involvement in adenoid cystic carcinoma (ACC) of
the head and neck have not been sufficiently assessed to guide a decision of prophylactic neck
dissection (ND). The objective of this study is to analyse the influence of ND on event-free
survival (EFS) for patients with cN0 ACC.
Patients and methods: A multicentre prospective study was conducted between 2009 and 2018.
Patients presenting cN0 non-metastatic ACC on any site, and who received surgery on the
tumour, were included. EFS was the main judgement criterion. A comparative survival anal-
ysis between the groups that received a ND versus those that did not was performed, using a
propensity score. Analyses were carried out using the R software.
Results: Between 2009 and 2018, 322 patients with cN0 ACC were included, out of which 58%
were female. The average age was 53 years. Tumours were in minor salivary glands in 58% of
cases, and 52% had T3/T4 stages.
ND was performed on 46% of patients. Out of them, seven had histological lymph node in-
vasion, out of which six had tumour infiltration in the mucosa of oral cavity.
After propensity score, the median EFS for N0 patients with ND was 72 months (95% Con-
fidence Interval (CI) [48e81]), compared to 73 months (95% CI [52e85]) for patients without
ND (HR Z 1.33; 95% CI [0.82e2.16]; p Z 0.2).
Conclusion: ND of cN0 patients does not provide any benefit on EFS, which suggests that its
application on such patients is not necessary.
ª 2020 Elsevier Ltd. All rights reserved.1. Background
AdenoidCysticCarcinoma (ACC)accounts for 1%ofhead
and neck cancers and 10% of salivary gland cancers [1].
It is characterised by slow evolution, rare lymph node
invasion and high rate of local and distant recurrences,
which make it a deadly tumour [2].
The therapeutic strategy remains unconsensual, with
the exception of surgical management at the localised
and resectable stage [3]. Guidelines are based on mostly
retrospective series [4,5].ACC is often described as having relatively infre-
quent lymphophilic extension. Lymph node metastases
(LNM) rates vary from 4% to 33% depending on the
tumour sites [6e8]. LNM is a factor of negative prog-
nosis [9e12].
The frequency of occult LNM (cN0pNþ) is low
(14%, according to Ning et al.) [13].
The need for prophylactic neck dissection (ND) on
cN0 patients is therefore questionable: the few studies
carried out so far have not shown any benefit in terms of
overall survival (OS) when ND was performed [14].
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impact on EFS of ND for cN0 ACC patients. The sec-
ondary objectives are to study this impact on local
recurrence-free survival (RFS), metastasis-free survival
(MFS) and OS.
2. Patients and methods
2.1. Population and database
A multicentre prospective inclusion of incident cases
was conducted from January 2009 to February 2018.
Data collection was carried out using a standardised
questionnaire. Data were integrated into the REFCOR
(French National Network on rare head and neck can-
cers) database. The comparative study protocol was
elaborated in 2018. Analyses were performed after
updating and quality control of the database.
Missing and inconsistent data were corrected after
reviewing the files. A second data quality control was
carried out by a checking of the histological reports.
Records of patients that were found to be pNþ after
dissection were reviewed.
Any patient managed in a REFCOR centre with a
confirmed ACC was included in the series.
Only patients without clinical LNM at the diagnostic
stage (cN0) who were surgically treated at the primary
tumour site were included.ACC
REFCOR database (2009-2018)
N = 670
ACC with EFS data and a confirmed diagnosis
N = 470
CAK Tx cN0 M0, surgery on T
N = 322
CAK Tx cN0 M0
Neck Dissec on = ND+
N = 149
CAK Tx cN0 M0




CAK Tx cN0 M0
Neck Dissec on = ND+
N = 96
CAK Tx cN0 M0 
No Neck Dissec on = ND-
N = 96
Fig. 1. FlowExclusion criteria were metastatic patients at the
diagnostic stage, unknown treatment status and under-
age patients <18 years (Fig. 1).
In order to take into account the type of post-
operative radiotherapy (PORT) and to verify the
absence of influence of this treatment on survival in the
compared groups, a survey was conducted among the
network’s radiotherapists.2.2. Propensity score matching
A propensity score analysis was conducted to minimise
the selection bias and potential confounding factors
between groups.
This score was calculated for each patient as the ex-
pected probability of receiving ND, based on a multi-
variate logistic regression that included the main
confounding factors associated with survival: age, body
mass index (BMI), tumour site and T stage. These
criteria were chosen following a meeting between expert
clinicians because of their clinical relevance. In the se-
ries, BMI and age were identified as significantly influ-
encing patient prognosis and included de facto. Only
variables known at the time of the surgery were eligible
[15]. Each patient was weighted by the inverse proba-
bility of being part of the group of patients with ND
(NDþ) versus the group without ND (ND), in orderExcluded (N = 200) :
• Histology different from ACC a er re-read (N =17) ; 
• EFS data missed (N = 183).
Excluded (N = 148) :
•cN+ (N = 48) ;
•cN status missed (N = 37) ;
• No surgery on the tumour site (N = 1) ;
• T status data missed (N = 62).
chart.
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tolerance (caliper) was set at 0.02.
Given the presence of missing data, multiple impu-
tation was used using the MICE method (R software).
The results obtained on the series before and after
imputation were compared in order to validate them.
Sensitivity analyses had been scheduled a priori: exclu-
sion of sinus tumours (where ND is only rarely recom-
mended) and exclusion of BMI (12% of missing data).
2.3. Evaluation criteria
EFS was defined as the time between diagnosis and local
or distant recurrence, death or the date of last follow-up
for censored patients.
OS was defined as the time between diagnosis and
death, or the date of last follow-up for censored
patients.
MFS was defined as the time between diagnosis and
distant recurrence, death or the date of last follow-up
for censored patients.
RFS was defined as the time between diagnosis and
local recurrence, death or the date of last follow-up for
censored patients.
2.4. Statistical analysis
The categorical variables were characterised by their
proportion and compared using Pearson’s chi-squared
test or Fisher’s exact test.
Continuous variables were described by their mean or
median and their range. They were then compared using
Student’s t-test or ManneWhitney test.
All statistical tests were two-sided. A p value less than
0.05 was considered statistically significant.
The KaplaneMeier method and a Cox model were
used to analyse EFS, OS, MFS and RFS.
Statistical analyses and survival curves were per-
formed using the R software (v.3.6.0 (2019-04-26)).
3. Results
3.1. Patient characteristics
Our sample included 322 patients from 33 centres with
cN0 ACC, a majority of which were female (58%; sex
ratio 1:4).
The mean age at diagnosis was 53 years (median 54
[18e90]). The average BMI at diagnosis was 25 kg/m2
(median 25 [16e46]).
Smoking and alcohol consumption were associated
with 31% and 14% of patients, respectively. Patients had
immunosuppression (diabetes or immunosuppressive
therapy) in 6% of cases.
Minor salivary glands were mainly affected (58%).
The parotid gland (27%), sinus cavities (25%), oralcavity (20%) and submandibular gland (15%) were the
four main tumour sites.
The proportion of patients treated for sinus tumours
varied among centres, depending on their degree of
specialisation in sinus surgery. Half of the patients had
advanced T-stages at diagnosis: 20% of T3 and 32% of T4.
All the 322 patients underwent surgery of the tumour
site: 46% of them NDþ, 149 patients, versus 173 ND.
Tumour resection margins were positive in 40% of
patients and close in 22% of patients.
The presence of a solid component representing
>30% of the tumour (histological grade 3), perineural
invasion and vascular embols was found in 20%, 68%
and 28% of patients, respectively.
Among the 149 patients who had a ND, histological
reports of 85 of them could be reviewed. Among those,
the results of 5 bilateral ND and 77 unilateral ND could
be analysed. The average number of nodes was 22,
median was 18 and range was [3e76].
PORT was performed on 75% of patients. Informa-
tion regarding the type of radiotherapy and the irradi-
ated site (on the tumour bed and/or lymph node bed)
was missing in 70% of cases.
For ND cN0 ACC patients, 85% of our surveyed
radiotherapists performed prophylactic irradiation
(50e60 Gy). In the case of NDþ, 57% of them per-
formed prophylactic irradiation even if pN0.
In addition, 13% of patients received chemotherapy
along with PORT.
The characteristics of the two patient groups are
presented in Table 1. They were comparable for the
majority of characteristics, with the exception of BMI
and tumour site.
Two groups matched by propensity score were
generated (96 pairs, n Z 194 patients). Matching erased
clinical differences between groups (Table 1).3.2. Characteristics of pNþ patients
Seven cN0 patients were found to be pNþ, which im-
plies an occult LNM rate of 5%. Four of them had
capsular effraction Table 2.
The tumour sites were oral cavity (4 patients),
maxillary sinus (1 patient), parotid gland (1 patient) and
submandibular gland (1 patient). Histological grade 1
was predominant.
The pNþ involvement in the patient whose tumour
site was parotid was a lymph node invasion by tumour
contiguity.
For two patients, tumour invasion was localised on a
boundary zone between two anatomical entities. The
tumour of the first patient was located between the
maxillary sinus and the oral cavity. It infiltrated the
palatal mucosa. The second patient’s tumour was
located between the submandibular gland and the oral
cavity. It infiltrated the mouth floor mucosa.
Table 1
Characteristics of patients according to “Neck Dissection”/“No Neck Dissection” group before and after propensity score matching (*p 0.05)
(NA Z data not available).
Before Matching After Matching
ND NDþ p value ND NDþ p value
Total 173 149 96 96
Age <65 131 114 0.87 75 71 0.5
65 42 35 21 25
NA 0
BMI <16.5 2 2 0.05* 1 2 0.84
Normal 138 105 76 75
30 13 24 19 19
NA 38
Sex Female 100 88 0.82 60 55 0.46
Male 73 61 36 41
NA 0
Tobacco No 112 95 0.56 58 63 0.45
Yes 48 47 38 33
NA 20
Alcohol No 132 123 0.44 70 77 0.23
Yes 25 18 26 19
NA 24
Immunodeficiency No 162 141 0.71 87 90 0.42
Yes 11 8 9 6
NA 0
Tumour site Parotid 36 50 0.003* 34 36 0.9
Oral cavity 36 27 24 23
Sinus 67 14 13 14
Submandibular 15 33 15 13
Pharynx 12 14 7 7
Larynx 1 8 1 1
Ear 5 3 2 2
NA 1
T Stage T1 40 31 0.34 28 25 0.88
T2 37 45 22 21
T3 34 29 20 19
T4 59 43 26 31
NA 4
Radiotherapy No 45 32 0.26 31 21 0.1
Yes 118 113 65 75
NA 14
Chemotherapy No 137 125 0.63 83 85 0.66
Yes 22 17 13 11
NA 21
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their oral cavity’s mucosa.
3.3. Survival
The median follow-up was 25 months.Table 2
Characteristics of pNþ patients. PNI Z perineural invasion. Area refers t
Patient Age Sex Tumour Site Mucosa
Infiltration
Localisation T
N1 56 M SUB MANDIBULAR Yes Mouth floor 2
N2 60 M MAXILLARY SINUS Yes Palate 4
N3 66 M ORAL CAVITY Yes Cheek 2
N4 73 F ORAL CAVITY Yes Mouth floor 2
N5 57 F ORAL CAVITY Yes Palate 4
N6 47 M ORAL CAVITY Yes Palate 1
N7 71 F PAROTID No NA 23.4. Main judgement criteria
Before the matching analysis, the median EFS of the
NDþ group was 72 months (95% Confidence Interval
(CI) [55e112]) versus 76 months (95% CI [59e114]) for















Close 48 5 yes II, III 1 yes
Positive 3 1 0 NA 1 NA
Positive 22 8 yes NA 3 yes
Positive 14 1 0 IIA NA yes
Positive 37 1 0 NA 1 yes
Positive 67 1 yes IIb 1 yes
Positive 35 1 yes IIb 1 yes
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[0.47e0.69]) for ND-patients (HR Z 1.24; 95% CI
[0.86e1.8]; p Z 0.2).
After matching by propensity score, the median EFS
of the NDþ group was 72 months (95% CI [48e81]),
compared to 73 months (95% CI [52e85]) for the ND-
group. The 5-year EFS rate for the NDþ group was
50% (95% CI [0.38e0.67]) versus 58% (95% CI
[0.45e0.72]) for the ND-group (HR Z 1.33; 95% CI
[0.82e2.16]; p Z 0.2) (See Fig. 2).3.5. Secondary judgment criteria (results expressed after
propensity score)
The rates of 5-year survival in the NDþ group
compared to the ND-group were:
- RFS: 60% (95% CI [0.47ee0.77]) for NDþ group versus
73% (95% CI [0.6ee0.87]) for the ND group (HR Z 1.4;
95% CI [0.79e2.4]; p Z 0.3);
- MFS: 63% (95% CI [0.42e0.77]) for the NDþ group versus
67% (95% CI [0.56e0.83]) for the ND group (HR Z 1.15;
95% CI [0.66ee2]; p Z 0.6);
- OS: 85% (95% CI [0.73e0.94]) for the NDþ group versus
88% (95% CI [0.76ee0.99]) for the ND group (HRZ 1.4;
95% CI [0.58e3.18]; p Z 0.5) (See Fig. 3).4. Discussion
Our study found a low rate of occult LNM and no
difference in EFS after adjustment on biases between the
two groups of patients treated with ND or not.
To our knowledge, our study is the first to assess the
influence of ND on EFS. It differs from previous studies
by analysing survival with a propensity score that allows
for a better comparison, despite the lack of random-
isation [16]. The relevance of the question is supported
by the finding in our series that patient characteristics
are balanced between the NDþ and ND groups,
suggesting that the decision to perform ND is not based
on a standardised attitude.Fig. 2. Event-free survival curves of patients with cN- ACC by neck dis
score matching (B).Inour series, the cNþ rate at the timeofdiagnosis is low
(11%, 48 patients). In comparison, Ning’s meta-analysis
finds a high variability of results (4%e33%) depending
on the series, with an average of 16% of cNþ [13].
For the main salivary glands, a literature review
suggests a 18.6% rate of LNM. The prevalence of LNM
for ACC is 14.5% for the parotid gland, 22.5% for the
submandibular gland and 24.7% for the sublingual
gland. In this study, cervical LNM occur more
frequently in the T3eT4 stage and are mainly found in
zones II and III [17].
Few studies present the occurrence rate of occult
LNM among the cN0 after ND. It varies from 8% to
23%, with an average of 14% in Ning’s meta-analysis
[7,13,17,18].
The variability of this rate can be explained by the
difference in the proportion of cN0 patients who
received ND, the number of lymph nodes collected and
the small size of the studied populations [19].
In our study, the occurrence of cN0pNþ among the
NDþ patients is low (5%). This rate could be artificially
lowered by the fact that our definition of ND does not
include the number of lymph nodes sampled due to 45%
of missing data. It could also be due to a possible
reclassification a posteriori as cNþ by technicians of a
few patients initially considered as cN0.
After reviewing the seven records of cN0pNþ pa-
tients, it is observed that six of the tumours shared a
common characteristic: they invaded the mucosa of the
oral cavity. The seventh case corresponded more to an
invasion by contiguity. These results are in line with
other series [8,20,21]. More unexpected is the high pro-
portion of grade 1 (5/7) among these patients, as histo-
logical grade is supposed to predict the risk of node
invasion. It is although difficult to make hypotheses out
of such a small number of patients.
Current data on ACC were insufficient to determine
whether prophylactic ND should be recommended for
cN0 patients: studies are mainly retrospective. Several of
them show the limited benefit in terms of survival of
treating patients with ND [8,14,22].section before propensity score matching (A) and after propensity
Fig. 3. ACC cN,recurrence-free survival (A), metastasis-free survival (B) and overall survival (C) curves by neck dissection (after pro-
pensity score matching).
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ommendations: for the main salivary glands, the Inter-
national Head/Neck Scientific Group recommends that
ND be performed in N0 patients only at the T3eT4
stage [17], whereas for sinus, lacrimal gland and external
auricular duct tumours with a low metastasis rate
(5.3%), it recommends not performing a ND [23].
For ACC in the oral cavity and oropharynx, an in-
ternational review recommends that, in the face of a
higher occult metastases rate within these sites, ND
should be performed when patients have negative
prognostic factors and postoperative radiotherapy is not
being considered [24]. Our study is in line with this
conclusion: involvement of the oral mucosa is probably
a risk factor of occult nodal involvement and should be
considered in the decision process. For ACC in the
larynx, an international review found only 12% LNM
and recommends not to perform ND in cN0
patients [25].
Our results are in line with these studies, showing that
ND does not bring any benefit in terms of survival for
cN0 patients. The trend towards better survival in the
ND-group is a strong argument to suggest that this
negative result is not only due to a lack of power. The
confidence interval of the matched HR (HR Z 1.33;
95% CI [0.82e2.16]) leaves little space for a HR below 1,
which would favour the ND.
PORT is often applied to patients with ACC, because
of the frequency of negative histological prognosiscriteria. It has a positive impact on the survival rate of
patients with advanced T-stage and positive margins [26].
In our series, the majority of patients received PORT.
In addition, both groups of NDþ versus ND patients
had PORT in the same proportion.
A possible explanation for the lack of observed
benefit in favour of ND could therefore be linked to
PORT, which seems e according to our survey of the
network’s radiotherapists e to be little influenced by the
use of ND: radiotherapists tend to include at least the
proximal nodes in their irradiation field, whether or not
the cN0 patient has had a ND. This finding supports the
absence of a potential bias induced by PORT.
Systematic ND can still be used to stage patients with
the pN classification, which can theoretically guide the
choice of post-operative treatment. However, it is an
excessively invasive procedure for 95% of the cN0 pa-
tients in our series: Whether being functional or radical,
ND remains a source of post-operative complications
and morbidity in 35% of cases [27]. Functional disorders
still occur frequently. They are often associated with
damage to the spinal nerve, but shoulder morbidity can
occur even if the nerve has been preserved [28,29].
However, the presence of LNM is a negative prog-
nostic factor [9,10,12,30]. ND is therefore recommended
if LNM are found during the initial assessment [4].
In order not to underestimate cNþ patients, we
recommend carrying out a qualitative pre-operative
assessment by imaging.
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deoxy-D-glucose coupled with a CT scan (PET-CT-
FDG) plays a major role in the detection and staging of
patients with head and neck cancer, but most studies
focus on squamous cell carcinoma (SCC) [31]. However,
ACC absorbs less FDG than SCC [32].
PET-CT-FDG could be an added value in the
assessment of disseminated disease for patients with
ACC, and therefore in determining treatment planning,
but still needs to be evaluated [33].
Sentinel lymph node (SLN) technique was validated
for the treatment of tumours of the oral cavity and
oropharynx in 2005 by a consensus conference [34]. It
enables to target the lymph node procedure and
morbidity to be reduced. Our study suggests that it may
be advisable to consider proposing the SLN technique for
ACC involving the mucosa of the oral cavity, especially
because they are the most suitable for this technique [29].
One of the limitations of our study is the number of
missing data: it involved seven of the variables with an
average of 6%. BMI variable had 12% missing data.
Sensitivity analyses were performed by excluding this
variable from our model. The results were not altered.
Moreover, the analysis of missing data by individual and
by variable showed a random distribution of these missing
data suggesting the feasibility of multiple imputation [35].5. Conclusion
The incidence of occult metastases in patients with cN0
ACC is low.
Patients not treated with ND do not show a differ-
ence in EFS compared to those treated with it, as long as
post-operative radiotherapy is still considered.
Our results suggest that systematic ND should not be
performed on cN0 patients with minor or major salivary
gland ACC, except for infiltrating tumours of the oral
cavity.
However, it is necessary to carry out a close pre-
operative assessment of the intervention and quality
imaging as well as early post-operative lymph node
monitoring.
Evaluation of the SLN technique for patients with oral
cavity ACC could be an alternative approach to ND.The REFCOR members
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Blanchard, N. Bonmardion, C. Borel, A. Bozorg-
Grayeli, R. Breheret, E. Brenet, P. Breton, I. Broyard,
L. Brugel, G. Calais, V. Calugaru, O. Casiraghi, E.
Cassagnau, L. Castillo, P. Ceruse, F. Chabolle, D.
Chevalier, J.C. Chobaut, O. Choussy, A. Cosmidis, A.
Coste, V. Costes, L. Crampette, S. Dakpe, V.Darrouzet, H. De Kermadec, P. Dessi, B. Devauchelle,
L. Digue, G. Dolivet, F. Dubrulle, S. Duflo, X. Dufour,
C. Even, S. Faivre, N. Fakhry, F. R. Ferrand, C. Fer-
ron, F. Floret, L. de Gabory, R. Garrel, L. Geoffrois, L.
Gilain, A. Giovanni, A. Girod, B. Guerrier, S. Hans, P.
Herman, P. Hofman, M. Housset, R. Jankowski, F.
Janot, F. Jegoux, M. Juliéron, M.-C. Kaminsky, F.
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